Eurizon Capital SGR S.p.A. Invests $86.74 Million in Amgen Inc. $AMGN

Eurizon Capital SGR S.p.A. purchased a new position in shares of Amgen Inc. (NASDAQ:AMGN) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 264,953 shares of the medical research company’s stock, valued at approximately $86,737,000.

A number of other hedge funds have also modified their holdings of AMGN. Capital World Investors grew its holdings in shares of Amgen by 11.5% during the 3rd quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock worth $5,303,578,000 after purchasing an additional 1,935,876 shares during the period. Geode Capital Management LLC grew its holdings in shares of Amgen by 7.8% during the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after purchasing an additional 1,035,779 shares during the period. Vanguard Group Inc. grew its holdings in shares of Amgen by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock worth $17,949,296,000 after purchasing an additional 961,975 shares during the period. National Bank of Canada FI grew its holdings in shares of Amgen by 237.7% during the 3rd quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company’s stock worth $346,076,000 after purchasing an additional 863,216 shares during the period. Finally, Van ECK Associates Corp grew its holdings in shares of Amgen by 71.8% during the 3rd quarter. Van ECK Associates Corp now owns 1,358,092 shares of the medical research company’s stock worth $383,254,000 after purchasing an additional 567,400 shares during the period. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Stock Performance

NASDAQ AMGN opened at $336.79 on Friday. The company has a market cap of $181.77 billion, a P/E ratio of 23.44, a P/E/G ratio of 3.38 and a beta of 0.44. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. The stock has a 50-day moving average of $342.53 and a two-hundred day moving average of $345.33. Amgen Inc. has a 1-year low of $267.83 and a 1-year high of $391.29.

Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $4.77 by $0.38. The company had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.Amgen’s revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the company posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, analysts anticipate that Amgen Inc. will post 22.37 EPS for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be given a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 3.0%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s payout ratio is currently 70.15%.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on AMGN. Piper Sandler lowered their price target on Amgen from $432.00 to $427.00 and set an “overweight” rating for the company in a report on Thursday, May 14th. Wall Street Zen upgraded Amgen from a “hold” rating to a “buy” rating in a report on Saturday, May 23rd. Rothschild & Co Redburn increased their price target on Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a report on Wednesday, February 18th. Deutsche Bank Aktiengesellschaft raised their target price on Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a report on Thursday, February 5th. Finally, Royal Bank Of Canada lifted their target price on Amgen from $360.00 to $370.00 and gave the company an “outperform” rating in a research report on Tuesday, April 7th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Amgen has a consensus rating of “Hold” and a consensus price target of $355.19.

Insiders Place Their Bets

In other news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the transaction, the senior vice president owned 7,009 shares in the company, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.85% of the stock is currently owned by corporate insiders.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.